Abstract: Disclosed herein are embodiments of compositions, methods and kits that describe ancillary reagent constructs for simultaneous immunological and morphological investigation of pathology specimens. The kits include reagents, possibly organized in panels, which give the pathologist additional confidence in making a diagnosis based on the morphology of a cell. Reagents can be used or selected to identify specific antigens or a class of antigens. The reagents further comprise detection agents, which are visible under standard microscopy in the presence of standard stains. The reagents, used on their own or as part of a kit, make possible immunological analysis simultaneously with pathology performed in the presence of standard stains.

Abstract: A method and system for performing single molecule proteomics utilizing a nanopore sensor to measure an electronic signature of protein or peptide being transported through the nanopore from a first chamber to a second chamber. The protein's electronic signature is a function of ionic current over time. The method and system utilizing an agent, such as guanidinium chloride, to bind to the nanopore's interior and provide an electroosmotic force within the nanopore. The electroosmotic force, in some embodiments, enables stretching and unfolding of the protein during transport through the nanopore. The agent may also or alternatively induce the unfolding of the protein before transport through the nanopore and/or provide force moving the protein through the nanopore.

Abstract: A first fluidic solution having a first ionic concentration is provided in a first fluidic reservoir in direct fluidic connection with a nanopore. A second fluidic solution, having a second ionic concentration, is provided in a second fluidic reservoir disposed in fluidic connection with the nanopore through a fluidic passage having at least one fluidic section in which the section length is greater than the section width. The electrical potential local to the fluidic passage is measured, and the resistance of both the fluidic passage the nanopore are determined based on the fluidic passage electrical potential. The fluidic passage resistance is compared with the nanopore resistance and at least one of the first and second ionic concentrations is adjusted based on the comparison. The measuring, determining, comparing, and adjusting steps are conducted until the fluidic passage resistance is between about 0.1 times and about 10 times the nanopore resistance.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: A method for manufacturing a biological field-effect transistor (BioFET) is disclosed. In some implementations, the method may include preparing a carbonaceous dispersion by adding a three-dimensional (3D) graphene into a solvent; depositing the carbonaceous dispersion onto a p-type silicon wafer; spin-coating a positive photoresist over the carbonaceous dispersion; forming source and drain terminals on the p-type silicon wafer, the source and drain terminals in contact with the 3D graphene of the carbonaceous dispersion; removing residual photoresist from the carbonaceous dispersion by placing the p-type silicon wafer in 1-methyl-2-pyrrolidone (NMP); and biofunctionalizing the carbonaceous dispersion with a molecular recognition element configured to alter one or more electrical properties of the Bio-FET in response to exposure of the molecular recognition element to the analyte.

Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells. Specifically described are methods to direct the lineage specific differentiation of hiPSC to sensitive neurons or neuronal fibers innervating the human skin, such as neural crest stem cells (NCPCs) and here called peripheral sensory neurons (PSNs) using novel culture conditions. It is also described a method for screening a biological agent in vitro. The PSNs obtained using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro tests or disease modelling, such as drug discovery assays, cell therapy on a higher scale, detecting a range of skin irritants and other compounds of interest, for studying skin aging mechanism, and for producing a dermocosmetic product.

Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The present invention relates to a method of creating a biomarker profile, the method comprising the steps of: obtaining a sample of biofluid from a subject, wherein the sample is stored on a sample collection apparatus; removing the sample from the sample collection apparatus; extracting nucleic acids from the sample; sequencing the extracted nucleic acids to generate sequence data; and analyzing the sequence data using a two-step analytical methodology to create the biomarker profile. The present invention is also directed to methods of determining the sex of an in utero fetus, predicting onset of a migraine in a subject, and of tracking athletic performance in a subject.

Abstract: Methods of writing data to a DNA strand by inserting data-encoding oligos or symbols into a DNA backbone. One particular method of synthesizing a DNA strand encoding data includes cleaving a DNA backbone into multiple segments, and pasting a plurality of data-encoding oligo symbols between the multiple segments, with the terminal ends of the segments joining homologous terminal ends of the symbols, resulting in the DNA strand encoding data comprising alternating segments and symbols.

Abstract: Systems and methods for flow cytometry. The methods comprise: labeling cells of a sample with Raman tags; causing the sample to flow through a microfluidic channel of a flow cytometer through which a laser beam passes; detecting Raman signals emitted from the Raman tags while being illuminated by the laser beam; and determining characteristics of the cells based on the detected Raman signals.

Abstract: The present invention pertains to a method for directly determining the biological activity of a Neurotoxin polypeptide in cells, comprising the steps of: a) incubating cells susceptible to Neurotoxin intoxication with a Neurotoxin polypeptide for a time and under conditions which allow for the Neurotoxin polypeptide to exert its biological activity; b) fixing the cells and, optionally, permeabilizing the cells with a detergent; c) contacting the cells with at least a first capture antibody specifically binding to the non-cleaved and Neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the Neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates; d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first de

Abstract: The present application is directed to a sensor for detection and/or concentration determination of metal ions in a fluid comprising a complexing agent suitable for binding the metal ions to be detected, detection means and a linker moiety, wherein the detection means comprises a polymer membrane with nanopores. The sensor according to the present application can be used for fast, highly selective and ultrasensitive detection of metal ions in a fluid, in particular of Cu2+ ions. With such a sensor a qualitative and/or quantitative detection of metal ions can be achieved, which can be useful in the diagnosis and/or monitoring of diseases linked to abnormal metal ion concentrations such as for example Alzheimer's disease.

Abstract: The present invention provides nucleic acid molecules comprising a MeCP2 expression cassette, the expression cassette comprising, in operable linkage from 5? to 3?: a 5? transcriptional control region comprising a promoter capable of driving transcription in neural cells; an open reading frame encoding a MeCP2 protein; translation control signals; a 3? untranslated region (3?UTR) comprising one or more of: (i) a binding site for mir-22; (ii) a binding site for mir-19; (iii) a binding site for miR-132; (iv) a binding site for miR124; and (v) an AU-rich element; and transcriptional termination signals; wherein the MeCP2 expression cassette is not more than about 5 kb in length. The invention further provides viral vectors, especially vectors derived from adeno-associated virus (AAV), for use in therapeutic delivery of such expression cassettes.

Abstract: A method of separating free target analyte from protein-bound target analyte is described. Such can include obtaining an aqueous sample containing a target analyte in a free form (free target analyte) and the target analyte in a protein-bound form (protein-bound target analyte), passing the aqueous sample through a size exclusion chromatography matrix with a molecular weight cut off sufficient to allow the free target analyte to permeate into pores of the size exclusion chromatography matrix and exclude the protein-bound target analyte, whereupon the free target analyte adheres to and is immobilized by the size exclusion chromatography matrix and the protein-bound target analyte does not adhere to by the size exclusion chromatography matrix, separating the free target analyte from the protein-bound analyte by removing the protein-bound target analyte from the size exclusion chromatography matrix, and eluting the free target analyte from the size exclusion chromatography matrix with an organic solvent.

Abstract: The present disclosure relates to a microfluidic device capable of mimicking a biological microenvironment thereby achieving control of a microenvironment with time through control of the diffusion of target elements between chambers by interrupting or generating fluid flow inside a channel, and a method for manufacturing the same, and the microfluidic device according to an aspect of the present disclosure can mimic the biological microenvironment which changes constantly with time via a simple temporary operation of generating or interrupting fluid flow in the channel mechanically and can control diffusion via a simple method, and accordingly, a complicated microenvironment can be reproduced since the number and arrangement of diffusion chambers and channels can be designed variously.

Abstract: The present invention relates to a mechanochemical based synthesis of perfluoropyridine monomers, polymers made using such monomers and methods of making and using articles comprising such polymers. Such perfluoropyridine monomers are easily chemically tuned have the strength needed for high temperature applications and the flexibility needed for low temperature applications. In addition, to the aforementioned monomers, a mechanochemical based synthesis for such perfluoropyridine monomers is provided. All of the aforementioned performance application advantages are also found in polymers comprising Applicants' perfluoropyridine monomers.

Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).

Abstract: A method of examining a possibility of a subject having pancreatic cancer, including measuring GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in a specimen collected from the subject.

Abstract: A number of variations may include a sterile kit that may include a tray constructed and arranged to hold the necessary items to access an Ommaya reservoir and the tray may define a plurality of other resources or indentations constructed and arranged to seat, hold, or house additional components of the sterile kit. The sterile kit may additionally include a paper towel, a fenestrated drape, a plurality of sponge applicators, at least one pouch of povidone-iodine, at least one retractable winged butterfly needle, at least one luer lock syringe, a 3-way stopcock, a plurality of collection vials with tops which may be screwed on to prevent the contents thereof from leaking or escaping, sterile pads, bandages including adhesive bandages, and other components.

Abstract: A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Abstract: The field of the DISCLOSURE lies in active materials for organic image sensors. The present disclosure relates to transparent N materials and/or to transparent P materials and their use in absorption layer(s), photoelectric conversion layer(s) and/or an organic image sensor and methods for their synthesis. The present disclosure also relates to photoelectric conversion layer(s) including an active material according to the present disclosure, to a device, including active material(s) according to the present disclosure or photoelectric conversion layer(s) according to the present disclosure. Moreover, the present disclosure relates to an organic image sensor including photoelectric conversion layer(s) according to the present disclosure.

Abstract: The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body.

Abstract: A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

Abstract: The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof, and more particularly, to the epitope, and an antibody or an antigen-binding fragment binding thereto. The epitope region of the human Trx1 antigen confirmed in the present invention may be effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is effective in improvement of performance of a breast cancer diagnosis kit due to excellent binding affinity for Trx1 and very high sensitivity and specificity, compared to a conventional anti-Trx1 antibody. Further, the accuracy and reliability of breast cancer diagnosis may significantly increase because exceptionally high sensitivity and specificity are exhibited by detecting the monoclonal antibody of the present invention, which specifically binds to Trx1, rather than detecting CA15-3, another conventional breast cancer diagnostic biomarker.

Abstract: The present disclosure relates to an antibody specifically binding to bovine pregnancy-associated glycoprotein 1 (bPAG1) or an antigen-binding fragment thereof. The present disclosure further relates to a hybridoma cell producing the antibody; a composition including the antibody as an effective ingredient for diagnosis of bovine pregnancy; and a kit for diagnosis of bovine pregnancy. The present disclosure also relates to a method of diagnosing bovine pregnancy. Binding specifically to bPAG1, which is a pregnancy-associated plasma protein in bovines, the antibody allows a simple diagnosis of pregnancy in animals such as bovines of which the reproduction is important, so that the antibody may be usefully applied in the livestock industry by increasing reproduction efficiency.

Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.

Abstract: The method of analyzing absorbance of one or more liquid samples (3) arranged in the wells (2) of a microplate (1) comprises the steps of setting a desired wavelength falling within the wavelength range of 380 nm-750 nm for absorbance measurement (101), illuminating the samples (3) using electromagnetic radiation having a bandwidth of at most 20 nm around the set wavelength (102), measuring radiant flux transmitted through each sample (3) (103), on the basis of measured radiant flux values, determining an absorbance value for each sample (3) (104), and visualizing the absorbance values on a display (12) as a matrix comprising a plurality of cells (23), each cell (23) corresponding to a well (2) of the microplate (1) (105). The set wavelength is used as an input for determining the visual properties of the cells (23).

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

Abstract: A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

Abstract: A device for detecting particles in air; said device comprising: a receiver for receiving a flow of air comprising particles; a particle capturing arrangement configured to transfer the particles from the flow of air to a liquid for collection of a set of particles in the liquid; a flow channel configured to pass a flow of the liquid comprising the set of particles through the flow channel; a light source configured to illuminate the set of particles in the flow channel, such that an interference pattern is formed by interference between light being scattered by the set of particles and non-scattered light from the light source; and an image sensor comprising a plurality of photo-sensitive elements configured to detect incident light, the image sensor being configured to detect the interference pattern.

Abstract: As with many human physiological systems, issues within the central nervous system can arise for individuals leading to a variety of neurological disorders including, but not limited to, Charcot-Marie-Tooth disease, Alzheimer' disease, Parkinson's disease, multiple sclerosis, myasthenia gravis, demyelination, and axonal degeneration. However, culture devices presently provide researchers with limitations in their research. Embodiments of the invention aims to address these various limitations and allow studies, methods and screenings which cannot be performed with prior art culture devices. These include reducing manufacturing complexity, volumes of pharmaceuticals and cells required, allowing use in fields other than neurobiology, improved adhesion within the desired micro-channel regions of the devices, and increasing cell survival in cultures.

Abstract: Provided herein are methods, compositions, and kits for assays, many of which involve amplification reactions such as digital PCR or droplet digital PCR. The assays may be used for such applications as sequencing, copy number variation analysis, and others. In some cases, the assays involve subdividing a sample into multiple partitions (e.g., droplets) and merging the partitions with other partitions that comprise adaptors with barcodes.

Abstract: The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.

Abstract: The present disclosure relates to a proximity sensor. The proximity sensor includes: a light emitter (for example, a vertical cavity surface emitting LASER (VCSEL)) configured to irradiate light to a target to be inspected; a first light receiver having a first crosstalk characteristic, configured to detect an external reflected light from a target to be inspected within a first detection region (for example, 0˜5 cm approximately); and a second light receiver having a second crosstalk characteristic different from the first crosstalk characteristic, configured to detect an external reflected light from a target to be inspected within a second detection region (for example, 3˜60 cm approximately) relatively further than the first detection region.

Abstract: The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the ?(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.

Abstract: Methods, devices, and systems for performing digital assays are provided. In certain aspects, the methods, devices, and systems can be used for the amplification and detection of nucleic acids. In certain aspects, the methods, devices, and systems can be used for the recognition, detection, and sizing of droplets in a volume. Also provided are compositions and kits suitable for use with the methods and devices of the present disclosure.

Abstract: Disclosed herein are systems and methods of estimating the autofluorescence (AF) signal and other non-target signals in each channel of a multi-channel image of a biological sample that is stained with one or more fluorescent labels. In some embodiments, the estimated autofluorescence signal can then be subtracted or masked from the multi-channel image. In some embodiments, the autofluorescence-removed multichannel image can then be use for further processing (e.g. image analysis, etc.).

Abstract: Aspects of the disclosure include a system for performing cytometry that can be operated in three operational modes. In one operational mode, a fluorescence image of a sample is obtained by exciting one or more fluorophore(s) with a top-hat-shaped excitation beam with a plurality of beams that are radiofrequency shifted relative to one another. In another operational mode, a sample can be illuminated successively over a time interval by a laser beam at a plurality of excitation frequencies in a scanning fashion to generate an image of the sample from the detected fluorescence. In another operational mode, the system can be operated to illuminate a plurality of locations of a sample concurrently by a single excitation frequency (e.g., a horizontal extent), which is generated, e.g., by shifting the central frequency of a laser beam by a radiofrequency and detected fluorescence is used to analyze the sample.

Abstract: A system is provided for identifying the presence of a target molecule or ion. The system comprises a solid support, and at least one chemical reagent applied to the solid support. Each chemical reagent produces a presumptive color indication that identifies or excludes the presence of a target molecule or ion.

Abstract: In accordance with one aspect of the presently disclosed inventive concepts, a metal aerogel includes a plurality of metal nanowires formed into a porous three-dimensional structure, where pores in the structure are anisotropic.

Abstract: Devices for magnetic 3d culture are described including magnetic lids/bases for single Petri plates and adjustable height cap for same. Similar devices for multi-magnet culture plates wherein multiwell plates have all adjacent magnets orientated in the opposite polarity, and methods of making same.

Abstract: The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

Abstract: A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: Embodiments of the present invention relate to a combination of experimental and computational workflows that allow characterization of skin and subcutaneous tissue microbial flora and its associated metabolome, aiming to first evaluate an individual's skin and subcutaneous tissue to determine if any skin condition is as a result of an imbalance or absence of commensal or mutualistic microorganisms or their associated metabolites. In particular, embodiments of the methods and the associated computational platform provided herein relate to conducting a customized or personalized test and obtaining customized or personalized information regarding the skin and subcutaneous tissue flora and its associated metabolome there from. This may be accomplished by simultaneously identifying hundreds of microorganisms or metabolites on an individual's skin and subcutaneous tissue and comparing the resulting profile to a previously compiled healthy profile from our database of skin profiles.

Abstract: Embodiments of apparatuses and methods for determining a positioning of sensors in a wound dressing are disclosed. In some embodiments, a wound monitoring and/or therapy system can include a wound dressing and a plurality of sensors configured to measure one or more wound characteristics. The wound monitor system can also include at least one positioning device configured to indicate position and/or orientation in the wound of a sensor of the plurality of sensors. In some embodiments, a detector can be configured to determine, based on the positioning data, the position and/or orientation in the wound of the sensor of the plurality of sensors. In some embodiments, the plurality of sensors can be positioned on a strip or string of material in communication with the positioning device.